

Genotype-stratified treatment for monogenic insulin resistance: a systematic review

Robert K. Semple^{1,2}, Kashyap A. Patel^{3,4}, Sungyoung Auh⁵, ADA/EASD PMDI* & Rebecca J. Brown⁵✉

Abstract

Background Monogenic insulin resistance (IR) includes lipodystrophy and disorders of insulin signalling. We sought to assess the effects of interventions in monogenic IR, stratified by genetic aetiology.

Methods Systematic review using PubMed, MEDLINE and Embase (1 January 1987 to 23 June 2021). Studies reporting individual-level effects of pharmacologic and/or surgical interventions in monogenic IR were eligible. Individual data were extracted and duplicates were removed. Outcomes were analysed for each gene and intervention, and in aggregate for partial, generalised and all lipodystrophy.

Results 10 non-randomised experimental studies, 8 case series, and 23 case reports meet inclusion criteria, all rated as having moderate or serious risk of bias. Metreleptin use is associated with the lowering of triglycerides and haemoglobin A1c (HbA1c) in all lipodystrophy ($n = 111$), partial ($n = 71$) and generalised lipodystrophy ($n = 41$), and in *LMNA*, *PPARG*, *AGPAT2* or *BSCL2* subgroups ($n = 72, 13, 21$ and 21 respectively). Body Mass Index (BMI) is lowered in partial and generalised lipodystrophy, and in *LMNA* or *BSCL2*, but not *PPARG* or *AGPAT2* subgroups. Thiazolidinediones are associated with improved HbA1c and triglycerides in all lipodystrophy ($n = 13$), improved HbA1c in *PPARG* ($n = 5$), and improved triglycerides in *LMNA* ($n = 7$). In *INSR*-related IR, rhIGF-1, alone or with IGFBP3, is associated with improved HbA1c ($n = 17$). The small size or absence of other genotype-treatment combinations preclude firm conclusions.

Conclusions The evidence guiding genotype-specific treatment of monogenic IR is of low to very low quality. Metreleptin and Thiazolidinediones appear to improve metabolic markers in lipodystrophy, and rhIGF-1 appears to lower HbA1c in *INSR*-related IR. For other interventions, there is insufficient evidence to assess efficacy and risks in aggregated lipodystrophy or genetic subgroups.

Plain language summary

The hormone insulin stimulates nutrient uptake from the bloodstream into tissues. In insulin resistance (IR), this action is blunted. Some rare gene alterations cause severe IR, diabetes that is difficult to control, and early complications. Many treatments have been suggested, but reliable evidence of their risks and benefits is sparse. We analysed all available reports describing treatment outcomes in severe IR. We found that the evidence is of low to very low quality overall. Injections of leptin, a hormone from fat tissue, or thiazolidinedione tablets that increase fat tissue both appear to improve diabetes control in people with reduced ability to make fat tissue. Injections of another treatment, insulin-like growth factor, appear to improve diabetes control in people with direct blockage of insulin action. There is a pressing need to improve evidence for treatment in these rare and severe conditions.

¹Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK. ²MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK. ³Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK. ⁴Department of Diabetes and Endocrinology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK. ⁵National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. *A list of authors and their affiliations appears at the end of the paper. ✉email: brownrebecca@nidk.nih.gov

Diabetes caused by single gene changes is highly heterogeneous in molecular aetiopathogenesis. It may be grouped into disorders featuring primary failure of insulin secretion, and disorders in which insulin resistance (IR), often severe, predates secondary failure of insulin secretion and diabetes. Monogenic IR is itself heterogeneous, encompassing primary lipodystrophy syndromes, primary disorders of insulin signalling, and a group of conditions in which severe IR is part of a more complex developmental syndrome¹.

Monogenic IR is rare but underdiagnosed. The commonest subgroup is formed by genetic lipodystrophy syndromes^{2,3}. A recent analysis of a large clinical care cohort unselected for metabolic disease suggested a clinical prevalence of lipodystrophy of around 1 in 20,000, with a prevalence of plausible lipodystrophy-causing genetic variants of around 1 in 7000⁴. Monogenic IR is important to recognise, because affected patients are at risk not only of micro- and macrovascular complications of diabetes, but also of complications such as dyslipidemia, pancreatitis, and steatohepatitis, especially in lipodystrophy syndromes⁵. Non-metabolic complications specific to individual gene defects may also occur, including hypertrophic cardiomyopathy and other manifestations of soft tissue overgrowth³. Diabetes is also commonly the sentinel presentation of a multisystem disorder, and recognition of complex syndromes in a diabetes clinic may trigger definitive diagnostic testing.

The only therapy licensed specifically for monogenic IR is recombinant human methionyl leptin (metreleptin), with licensed indications encompassing a subset of patients with lipodystrophy and inadequate metabolic control. The current license in the USA is restricted to generalised lipodystrophy, but in Europe, it extends to some patients with partial lipodystrophy. A substantial proportion of the body of evidence considered in licensing addressed patients ascertained by the presence of clinical lipodystrophy, and the role of genetic stratification in the precision treatment of lipodystrophy has not been systematically addressed. Many other medications and other treatment options are also widely used in monogenic IR, although not licensed for that specific subgroup. Such use draws on the evidence base and treatment algorithms developed for type 2 diabetes. Several forms of monogenic IR have molecular and/or clinical attributes that suggest potential precision approaches to treatment.

We sought now to undertake a systematic review of the current evidence guiding the treatment of monogenic IR stratified by genetic aetiology, to assess evidence for differential responses to currently used therapies, to establish gaps in evidence, and to inform future studies. This systematic review is written on behalf of the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) *Precision Medicine in Diabetes Initiative* (PMDI) as part of a comprehensive evidence evaluation in support of the 2nd International Consensus Report on Precision Diabetes Medicine⁶. The PMDI was established in 2018 by the ADA in partnership with the EASD to address the burgeoning need for better diabetes prevention and care through precision medicine⁷.

Our analyses show that metreleptin and thiazolidinediones appear to lower HbA1c, triglycerides, and body weight in patients with lipodystrophy of all genotypes, and rhIGF-1 appears to lower HbA1c in patients with *INSR*-related IR. For other interventions, there is insufficient evidence to assess efficacy and risks.

Methods

Inclusion criteria and search methodology. To assess the treatment of severe IR of known monogenic aetiology, with or without diabetes mellitus, including generalised and partial lipodystrophy and genetic disorders of the insulin receptor, we

developed, registered and followed a protocol for a systematic review (PROSPERO ID CRD42021265365; registered July 21, 2021)⁸. The study was reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Filtering and selection of studies for data extraction were recorded using the Covidence platform (<https://www.covidence.org>, Melbourne, Australia).

We searched PubMed, MEDLINE and Embase from 1987 (the year before the identification of the first monogenic aetiology of IR) to June 23, 2021 for potentially relevant human studies in English. We used broad search terms designed to capture the heterogeneity of monogenic IR and its treatments. We searched for studies addressing 1. Severe IR due to variant(s) in a single gene OR 2. Congenital generalised or familial partial lipodystrophy due to variant(s) in a single gene. We selected only studies that reported a treatment term, including but not limited to the mention of 1. Thiazolidinediones (TZD), 2. Metreleptin, 3. SGLT2 inhibitors, 4. GLP-1 analogues, 5. Bariatric surgery (all types), 6. Recombinant human IGF-1 or IGF-1/IGFBP3 composite, 7. U-500 insulin. No interventions were excluded in the primary search. In addition to the automated search, we hand searched reference lists of relevant review articles. Given the rarity of monogenic IR, no study types were excluded in the initial search. We ultimately considered experimental studies, case reports, and case series. The full search strategy is described in Supplementary Table 1.

Study selection for data extraction was performed in two phases, namely primary screening of title and abstract, then full text review of potentially eligible articles. Two authors independently evaluated eligibility, with discrepancies resolved by a third investigator. We excluded publications without original data, such as reviews, editorials, and comments, and those solely addressing severe IR or lipodystrophy of unknown or known non-monogenic aetiology, including HIV-related or other acquired lipodystrophies, or autoimmune insulin receptoropathy (Type B insulin resistance). Studies in which no clear categorical or numerical outcome of an intervention was reported, or in which interventions were administered for less than 28 days were also excluded.

Data extraction and outcome assessments. One author extracted data from each eligible study using data extraction sheets. Data from each study was verified by 3 authors to reach a consensus. Data were extracted from text, tables, or figures. Study investigators were contacted for pertinent unreported data or additional details where possible, most commonly genetic aetiology of insulin resistance in reported patients, and outcome data.

Data extracted for each study included first author, publication year, country, details of intervention, duration of follow-up, study design, and number of participants. Subject-level data were extracted for outcomes of interest, including sex, genetic cause of severe insulin resistance (gene name, mono- vs biallelic *INSR* pathogenic variant), phenotypic details of severe IR/lipodystrophic subtype (generalised vs partial lipodystrophy; associated syndromic features). Subject level outcome data were extracted prior to and after the longest-reported exposure to the intervention of interest for haemoglobin A1c (A1c), body mass index, serum triglyceride, ALT, or AST concentration, any index of liver size or lipid content, and total daily insulin dose. Potential adverse effects of interventions were recorded, including urinary tract infection, genital candidiasis, hypoglycemia, excessive weight loss, pancreatitis, soft tissue overgrowth, and tumour formation.

Risk of bias and certainty of evidence assessment. The quality of extracted case reports and case series was assessed using NIH

Study Quality Assessment Tools⁹ by a single reviewer and verified by 2 additional reviewers. Grading of the overall evidence for specific research questions was undertaken as detailed in¹⁰.

Statistics and reproducibility. Extracted data were managed using Covidence and analysed with SAS version 9.4. Pooled analysis was undertaken for all combinations of genotype and intervention for which sufficient numbers were reported, as well as for aggregated lipodystrophies, and generalized and partial subgroups of lipodystrophy. Generalized Estimating Equation models were used with time as a fixed factor and study as a random factor to examine treatment effects. Serum triglyceride concentrations were analyzed with and without log transformation. Data were summarized using estimated least-squared means with corresponding 95% confidence intervals.

Reporting summary. Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Results

Identification of eligible studies. Initial searching identified 2933 studies, to which 117 were added from the bibliography reviews. 256 articles remained after the screening of titles and abstracts, and 44 after full text screening (Fig. 1).

Included studies addressed limited interventions and most had a high risk of bias. The 44 studies analysed and the assessment of their quality are summarised in Table 1 and detailed in Supplementary Data 1. Study quality was assessed as being fair in 15

cases and poor in 29 cases, including all case reports. This was primarily due to the high risk of bias, particularly related to the lack of a control group for all studies. Three of the 44 studies included in further analysis included only individuals already described in other reports and were discarded, leaving 41 studies for final analysis. These comprised 10 non-controlled experimental studies, 8 case series and 23 individual case reports (Table 1). No controlled trials were found. Individuals reported in the studies included 90 with partial lipodystrophy (72 due to *LMNA* mutation and 15 due to *PPARG* mutation), 42 with generalized lipodystrophy (21 *AGPAT2*, 21 *BSCL2*, 2 *LMNA*), and 19 with IR due to *INSR* mutation(s). Among the interventions described, only the responses to metreleptin (111 recipients), thiazolidinediones (13 recipients) and rhIGF-1 (alone or as a composite with IGFBP3) (17 recipients) were described in more than 5 cases (Table 1). This meant that for the large preponderance of possible genotype-treatment combinations no specific data were recovered (Supplementary Table 2). Full outcome data extracted are summarised in Supplementary Data 2, and subject-level data are shown in Supplementary Figures 1 through 8 with raw data provided in Supplementary Data 2.

Metreleptin treatment was associated with improved metabolic control in lipodystrophy. In our registered systematic review plan we posed several subquestions about treatment of monogenic IR subtypes that we felt were tractable. The first related to the risks and benefits (assessed by side effects, A1c, serum triglyceride concentration, body mass index (BMI), and indices of fatty liver) of metreleptin in patients with different monogenic subtypes of lipodystrophy. The response to metreleptin was




Fig. 1 PRISMA diagram. PRISMA flow diagram of publications evaluated based on the search strategy.

Table 1 Summary characteristics of included studies.

| Study types | Number of studies |
|--|--|
| Case reports | 23 |
| Non-randomised experimental study | 10 |
| Case series | 8 |
| Study Quality* | Number of studies |
| Good | 0 |
| Fair | 15 |
| Poor | 30 |
| Phenotypes | Number of participants |
| Partial lipodystrophy | 90 (72 <i>LMNA</i> , 15 <i>PPARG</i> , 2 <i>PLIN1</i> , 1 <i>PIK3R1</i>) |
| Generalised lipodystrophy | 56 (21 <i>AGPAT2</i> , 21 <i>BSCL2</i> , 1 <i>PTRF</i> , 2 <i>LMNA</i>) |
| Insulin receptor | 19 (7 Monoallelic, 12 Biallelic) |
| Intervention | Number of participants [#] |
| Metreleptin | 111 (71/40/0) |
| rhIGF-1 or rhIGF-1/IGFBP3 composite | 17 (0/0/17) |
| Thiazolidinedione | 13 (12/1/0) |
| Metformin | 5 (2/1/2) |
| Bariatric surgery | 4 (4/0/0) |
| SGLT2i | 2 (1/1/0) |

*Based on NHLBI quality assessment tool; [#]Numbers in brackets are for partial lipodystrophy/generalised lipodystrophy/insulin receptor individuals respectively. *rhIGF-1* recombinant human insulin-like growth factor 1, *IGFBP3* insulin-like growth factor binding protein 3, *SGLT2i* sodium-glucose co-transporter-2 inhibitor

described in 111 people (71 with partial lipodystrophy, 40 with generalised lipodystrophy)^{11–23}. Metreleptin was administered for 19 ± 20 months (median 12, range 1–108) and was associated with lowering of A1c in aggregated lipodystrophy, in generalised and partial subgroups, and in all genetic subgroups for whom sufficient patients were reported, namely those with *LMNA*, *PPARG*, *AGPAT2* and *BSCL2* mutations (0.5 to 1.5% least square mean reduction) (Level 3 evidence, Supplementary Data 3, Fig. 2). Metreleptin treatment was also associated with lowering of serum triglyceride concentration in aggregated lipodystrophy, in generalised and partial subgroups, and in those with *LMNA*, *PPARG*, *AGPAT2* and *BSCL2* mutations (92 to 1760 mg/dL least square mean reduction for analyses of untransformed data) (Level 3 evidence, Supplementary Data 3, Fig. 2). BMI was lower after treatment in aggregated lipodystrophy, in generalised and partial subgroups, and in those with *LMNA* or *BSCL2* mutations, but not *PPARG* or *AGPAT2* mutations (Level 3 evidence, Supplementary Data 3, Fig. 2). Liver outcomes reported were too heterogeneous to analyse in aggregate. Only a single adverse event, namely hypoglycemia, was reported.

Thiazolidinedione treatment showed variable efficacy in limited studies. We next addressed the evidence of the risks and benefits of thiazolidinediones (TZDs) in patients with lipodystrophy. We were specifically interested in any evidence of a greater or lesser response in partial lipodystrophy caused by *PPARG* variants than in other lipodystrophy subtypes, as TZDs are potent ligands for the product of the *PPARG* gene, the master regulator of adipocyte differentiation. The response to TZDs was described in only 13 people, however (12 FPLD, 1 CGL)^{24–34}. TZDs were administered for 29 ± 28 months (median 24, range 2–96). TZD use was associated with improved A1c in aggregated lipodystrophy (least square mean reduction 2.2%) and in *PPARG*-related but not *LMNA*-related partial lipodystrophy (Level 4 evidence,

Supplementary Data 3, Fig. 3). Serum triglyceride concentration decreased in aggregated lipodystrophy and in those with *LMNA*-related but not *PPARG*-related partial lipodystrophy (Level 4 evidence, Supplementary Data 3, Fig. 3). No adverse events were reported.

rhIGF-1 treatment in INSR-related IR was associated with improvement in A1c. Our last specific question related to the risks (e.g. tumours, hypoglycemia, cardiac hypertrophy, other soft tissue overgrowth) and benefits (assessed by A1c) of recombinant human IGF-1 (rhIGF-1) or IGF-1/IGFBP3 composite in patients with pathogenic *INSR* variants. The response to rhIGF-1 was described in 17 people with pathogenic *INSR* variants for a mean of 45 ± 81 months (median 9, range 1–288)^{35–46}. In *INSR*-related IR, we found that use of rhIGF-1, alone or as a composite with IGFBP3, was associated with improvement in A1c, and this was true also in subgroups with monoallelic and biallelic variants (1.5 to 2% least square mean reduction, Level 4 evidence, Supplementary Data 3, Fig. 4). One instance of increased soft tissue overgrowth and two episodes of hypoglycemia was reported.

Many questions about genotype-stratified treatment were not addressed. While many other interesting and clinically relevant questions arise about other potential genotype-specific responses to therapy in monogenic IR, the small size or absence of other genotype by treatment groups precluded the drawing of conclusions about risks and benefits, including for very widely used medications such as metformin^{26,47–49}, newer agents commonly used in type 2 diabetes including SGLT2 inhibitors^{50,51} and GLP-1 agonists, and non pharmacologic interventions such as bariatric surgery^{52–54}.

Discussion

Thirty-five years since *INSR* mutations were identified in extreme IR^{55,56}, and 23 years since the first monogenic cause of lipodystrophy was reported⁵⁷, many different forms of monogenic IR are known^{1–3,58}. These are associated with substantial early morbidity and mortality, ranging from death in infancy to accelerated complications of diabetes and fatty liver disease in adulthood, depending on the genetic subtype. Several opportunities for genotype-guided, targeted treatment are suggested by the causal genes, and so we set out to review the current evidence guiding the treatment of monogenic IR stratified by genetic aetiology. We found a paucity of high-quality evidence (all levels 3 to 4). No controlled trials of any intervention were identified, and there was substantial heterogeneity of study populations and intervention regimens, even for the same interventional agent.

The evidence which we did find, from a small number of uncontrolled experimental studies, augmented by case series and numerous case reports, suggests that metreleptin offers metabolic benefits across different lipodystrophy subtypes, in keeping with its licensing for use in some patients with lipodystrophy in both Europe and the USA. Notably, the evidence base considered by licensing authorities was larger than the one we present, including many studies of phenotypically ascertained lipodystrophy that included acquired or idiopathic disease. In contrast, we have addressed solely individuals with lipodystrophy caused by variation in a single gene. The limited data we identified do not clearly support differential effects among different monogenic lipodystrophy subgroups, but for many subtypes numbers reported are very small. Moreover, although responses appear comparable for partial and generalised lipodystrophy, this is highly likely to reflect selection bias in studies of partial lipodystrophy towards those with more severe metabolic complications and lower baseline serum leptin concentrations.




Fig. 2 Effects of metreleptin in monogenic forms of lipodystrophy. Least square mean change in (a) Hemoglobin A1c (A1c), (b) Log₁₀ serum triglyceride concentration and (c) Body Mass Index (BMI) in patients with partial lipodystrophy, generalized lipodystrophy, all forms of lipodystrophy, and subgroups with *PPARG*, *LMNA*, *BSC12*, and *AGPAT2* mutations. Error bars represent 95% confidence intervals. N = 64, 38, 102, 12, 52, 17, and 20 for change in A1c in partial lipodystrophy, generalized lipodystrophy, all lipodystrophy, *PPARG*, *LMNA*, *BSC12*, and *AGPAT2*-associated lipodystrophy, respectively. N = 66, 40, 106, 12, 54, 19, and 20 for change in log₁₀ triglycerides in partial lipodystrophy, generalized lipodystrophy, all lipodystrophy, *PPARG*, *LMNA*, *BSC12*, and *AGPAT2*-associated lipodystrophy, respectively. N = 47, 14, 61, 10, 35, 8, and 7 for change in BMI in partial lipodystrophy, generalized lipodystrophy, all lipodystrophy, *PPARG*, *LMNA*, *BSC12*, and *AGPAT2*-associated lipodystrophy, respectively.




Fig. 3 Effects of thiazolidinediones in monogenic forms of lipodystrophy. Least square mean change in (a) Hemoglobin A1c (A1c), (b) Log₁₀ serum triglyceride concentration and (c) Body Mass Index (BMI) in patients with partial lipodystrophy, generalized lipodystrophy, all forms of lipodystrophy, and subgroups with *PPARG*, and *LMNA* mutations. Error bars represent 95% confidence intervals. N = 5, 5, and 10 for change in A1c and change in log₁₀ triglycerides in *PPARG*, *LMNA*, and all lipodystrophy, respectively. N = 1, 5, and 6 for change in BMI in *PPARG*, *LMNA*, and all lipodystrophy, respectively.

A clear opportunity for precision diabetes therapy in monogenic IR is offered by the IR and lipodystrophy caused by mutations in *PPARG*, which encodes the target for thiazolidinediones (TZDs) such as pioglitazone^{59,60}. *PPARG* is a nuclear receptor that serves as the master transcriptional driver of adipocyte differentiation, and so as soon as *PPARG* mutations were




Fig. 4 Effects of recombinant human Insulin-like Growth Factor-1 (rhIGF) alone or in combination with Insulin-like Growth Factor Binding Protein-3 (IGFBP3) in patients with *INSR* mutations. Least square mean change in hemoglobin A1c (A1c), in all patients with *INSR* mutations, and in subgroups with biallelic and monoallelic mutations. Error bars represent 95% confidence intervals. N = 7, 6, and 13 for biallelic, monoallelic, and all *INSR* mutations.

identified to cause severe IR, there was interest in the potential of TZDs as specific treatments. Although we found small scale evidence supporting greater A1c reduction with TZDs in *PPARG* vs. *LMNA*-related lipodystrophy, only 5 patients with *PPARG*-related lipodystrophy in whom TZD effects were clearly described were reported, and responses were inconsistent. Thus, it remains unclear whether people with IR due to *PPARG* variants are more or indeed less sensitive to TZDs than people with other forms of lipodystrophy. Loss-of-function *PPARG* mutations are the second commonest cause of familial partial lipodystrophy², and the function of coding missense variants in *PPARG* has been assayed systematically to accelerate genetic diagnosis⁶¹, so the opportunity to test genotype-related therapy in *PPARG*-related IR seems particularly tractable in future.

Other obvious questions about the targeted treatment of monogenic, lipodystrophic IR are not addressed by current evidence. Important examples relate to the risks and benefits of treatments used in type 2 diabetes such as GLP-1 agonists and SGLT2 inhibitors. It is rational to suppose that these medications, which decrease weight as well as improve glycaemia in those with

raised BMI and diabetes, may also be efficacious in lipodystrophy even where BMI is normal or only slightly raised. This is because in both situations adipose storage capacity is exceeded, leading to fat failure. It is the offloading of overloaded adipose tissue, rather than the baseline BMI/adipose mass, which underlies the efficacy of therapy. However, GLP-1 agonists are contraindicated in those with prior pancreatitis, while SGLT2 inhibitor use can be complicated by diabetic ketoacidosis. In untreated lipodystrophy pancreatitis is common, yet this is due to hypertriglyceridaemia, which is likely to be improved by GLP-1 agonist use, while excessive supply of free fatty acids to the liver may promote ketogenesis. Thus, assessment of both classes of drugs in lipodystrophy and its genetic subgroups will be important to quantify risks and benefits, which may be distinct from those in obesity-related diabetes.

A further question we prespecified related to the use of rhIGF1 in people with severe IR due to *INSR* mutations. This use of rhIGF-1 was first described in recessive *INSR* defects in the early 1990s⁴⁴, and several studies of rhIGF-1 therapy of duration less than 28 days in people with *INSR* mutations have provided proof of concept for acute metabolic benefits (summarized in³⁸). This use of rhIGF-1 is based on the rationale that IGF-1 activates a receptor and signalling pathway very closely similar to those activated by insulin. Based on case reports, case series and narrative reviews, rhIGF-1 is now commonly used in neonates with extreme IR due to biallelic *INSR* mutations, although, unlike metreleptin in lipodystrophy, this use is still unlicensed. Our review of published data, which was limited to durations of intervention greater than 28 days, is consistent with glycaemic benefits of rhIGF-1, alone or in composite form with its binding protein IGFBP3, in people with *INSR* mutations. Nevertheless, such studies are challenging to interpret and are potentially fraught with bias of different types, particularly publication bias favouring positive outcomes. Responses to rhIGF1 are also challenging to determine in uncontrolled studies as small differences in the residual function of mutated receptors can have substantial effects on the severity and natural history of the resulting IR, yet relatively few *INSR* mutations have been studied functionally. This underlines the narrow nature of, and substantial residual uncertainty in, the evidence base for the use of rhIGF-1 in monogenic IR.

There are several reasons why important questions about the precision treatment of monogenic IR have not been settled. Although severe autosomal recessive IR is usually detected in infancy, commoner dominant forms of monogenic IR are often diagnosed relatively late, often only after years of management based on presumptive diagnoses of type 2 or sometimes type 1 diabetes. Initial management as type 2 diabetes means that by the time a clinical and then genetic diagnosis is made, most patients have been treated with agents such as metformin, and increasingly SGLT2 inhibitors or GLP-1 agonists, outside trial settings. It is not clear that harm is caused by such use of drugs with well-established safety profiles and efficacy in type 2 diabetes, but the lack of systematic data gathering precludes the identification of specific drug-genotype interactions. Moreover, because attempts to gather evidence for monogenic IR treatment have tended to focus on high-cost adjunctive therapies such as metreleptin, the evidence base for their use is better developed, although controlled trials are lacking. Licensing of high-cost treatments such as metreleptin in lipodystrophy, while effects of many more commonly used, cheaper drugs with well-established safety profiles lack formal testing in monogenic IR is potentially problematic, skewing incentives and guidelines towards expensive therapy before optimal treatment algorithms have been established.

Other challenges in conducting trials in monogenic IR arise from the exquisite sensitivity of IR to exacerbating factors such as

puberty, diet, and energy balance. This creates a signal to noise problem particularly problematic in uncontrolled studies, in which non-pharmacological components of interventions such as increased support for behavioural change may confound attribution of beneficial outcomes to pharmacological agents tested.

The key question now is how the evidence base for managing monogenic severe IR can be improved in the face of constraints in studying rare, clinically heterogeneous, and geographically dispersed patients who are often diagnosed late with a condition that is exquisitely environmentally sensitive. Growing interest in and development of methodologies for clinical trials in rare disease⁶², including Bayesian methodologies^{63,64}, and hybrid single- and multi-site designs⁶⁵ offer hope for future filling of evidence gaps. One important and pragmatic opportunity arises from the development of large regional, national and international networks and registries for lipodystrophy (e.g. the Europe-based ECLIP registry⁶⁶), allied to emergence of randomised registry-based trial (RRT) methodology^{67,68}. RRTs have attracted increasing interest in several disease areas and are particularly suitable for evaluation of agents with well-established safety profiles. When a simple randomisation tool is deployed in the context of a registry, RRTs can offer rapid, cost-effective recruitment and high external validity (i.e. relevance to real world practice). In monogenic IR this would permit questions to be addressed about optimal usage of different common medications in different genetic subgroups, including the order of introduction of therapies, and their optimal combinations. The quality of such studies will critically rely on good registry design and quality and completeness of data capture^{67,68}.

In summary, severe monogenic IR syndromes are clinically and genetically heterogeneous, with high early morbidity and mortality. However, despite opportunities for targeted therapy of some monogenic subgroups based on the nature of the causal gene alteration, the evidence for genotype-stratified therapy is weak. This is in part because of the rarity and frequent late diagnosis of monogenic IR, but also because therapeutic research to date has focused largely on phenotypically ascertained cross cutting diagnoses such as lipodystrophy. We suggest that approaches such as RRTs hold the best hope to answer some of the persisting major questions about precision treatment in monogenic IR.

Data availability

All data used in this review is available from publicly available and herein referenced sources. A list of included studies is provided in Supplementary Data 1. All data generated or analyzed during this study are included in this published article and its supplementary information files. Source data for the figures are available as Supplementary Data 2.

Received: 21 April 2023; Accepted: 20 September 2023;

Published online: 05 October 2023

References

1. Bonnefond, A. & Semple, R. K. Achievements, prospects and challenges in precision care for monogenic insulin-deficient and insulin-resistant diabetes. *Diabetologia* **65**, 1782–1795 (2022).
2. Lim, K., Haider, A., Adams, C., Sleight, A. & Savage, D. B. Lipodystrophy: a paradigm for understanding the consequences of “overloading” adipose tissue. *Physiol. Rev.* **101**, 907–993 (2021).
3. Semple, R. K., Savage, D. B., Cochran, E. K., Gorden, P. & O’Rahilly, S. Genetic syndromes of severe insulin resistance. *Endocr. Rev.* **32**, 498–514 (2011).
4. Gonzaga-Jauregui, C. et al. Clinical and molecular prevalence of lipodystrophy in an unascertained large clinical care cohort. *Diabetes* **69**, 249–258 (2020).
5. Brown, R. J. et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. *J. Clin. Endocrinol. Metab.* **101**, 4500–4511 (2016).

6. Deirdre, K. et al. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. *Nat. Med.* In press <https://doi.org/10.1038/s41591-023-02502-5> (2023).
7. Nolan, J. J. et al. ADA/EASD precision medicine in diabetes initiative: an international perspective and future vision for precision medicine in diabetes. *Diabetes Care* **45**, 261–266 (2022).
8. *Effects of pharmacologic and non-pharmacologic interventions on metabolic control in severe insulin resistance due to lipodystrophy or genetic insulin receptoropathy*, https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=265365 (2021).
9. *Study Quality Assessment Tools*, <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>
10. Sherifali, D. et al. *Methods. Can. J. Diabetes* **42**, S6–S9 (2018).
11. Musso, C., Major, M. L., Andres, E. & Simha, V. Metreleptin treatment in three patients with generalized lipodystrophy. *Clin. Med. Insights Case Rep.* **9**, 123–127 (2016).
12. Beltrand, J. et al. Resistance to leptin-replacement therapy in Berardinelli-Seip congenital lipodystrophy: an immunological origin. *Eur. J. Endocrinol.* **162**, 1083–1091 (2010).
13. Vatie, C. et al. Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes. *Orphanet. J. Rare Dis.* **14**, 177 (2019).
14. Beltrand, J. et al. Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipodystrophy. *Pediatrics* **120**, e291–e296 (2007).
15. Chong, A. Y., Lupsa, B. C., Cochran, E. K. & Gorden, P. Efficacy of leptin therapy in the different forms of human lipodystrophy. *Diabetologia* **53**, 27–35 (2010).
16. Maeda, M., Maeda, T., Ebihara, K. & Ihara, K. The long-term management of congenital generalized lipodystrophy (Berardinelli-Seip syndrome): the clinical manifestations of Japanese sibs for approximately 20 years. *Clin. Pediatr. Endocrinol.: Case Rep. Clin. Invest.: Off. J. Jpn Soc. Pediatr. Endocrinol.* **28**, 139–145 (2019).
17. Ebihara, K. et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. *J. Clin. Endocrinol. Metab.* **92**, 532–541 (2007).
18. Ajluni, N., Dar, M., Xu, J., Neidert, A. H. & Oral, E. A. Efficacy and safety of metreleptin in patients with partial lipodystrophy: lessons from an expanded access program. *J. Diabetes Metabol.* **7** <https://doi.org/10.4172/2155-6156.1000659> (2016).
19. Sekizkardes, H., Cochran, E., Malandrino, N., Garg, A. & Brown, R. J. Efficacy of metreleptin treatment in familial partial lipodystrophy due to PPARG vs LMNA pathogenic variants. *J. Clin. Endocrinol. Metab.* **104**, 3068–3076 (2019).
20. Simha, V. et al. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. *J. Clin. Endocrinol. Metab.* **97**, 785–792 (2012).
21. Takeyari, S. et al. Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report. *Clin. Pediatr. Endocrinol.: Case Rep. Clin. Investigations: Off. J. Jpn Soc. Pediatr. Endocrinol.* **28**, 1–7 (2019).
22. Oral, E. A. et al. Leptin-replacement therapy for lipodystrophy. *N. Engl. J. Med.* **346**, 570–578 (2002).
23. Park, J. Y., Javor, E. D., Cochran, E. K., DePaoli, A. M. & Gorden, P. Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. *Metabolism* **56**, 508–516 (2007).
24. Chaves, C., Chaves, M., Anselmo, J. & César, R. Successful long-term use of pioglitazone in Berardinelli-Seip lipodystrophy-associated diabetes. *Endocrinol. Diabetes Metab. Case Rep.* **2021** <https://doi.org/10.1530/edm-20-0183> (2021).
25. Collet-Gaudillat, C., Billon-Bancel, A. & Beressi, J. P. Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report. *Diabetes Metab.* **35**, 151–154 (2009).
26. Gambineri, A. et al. Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin. *Eur. J. Endocrinol.* **159**, 347–353 (2008).
27. Moreau, F. et al. Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report. *Diabetes Metab.* **33**, 385–389 (2007).
28. Owen, K. R., Donohoe, M., Ellard, S. & Hattersley, A. T. Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene. *Diabetes Med.* **20**, 823–827 (2003).
29. Simha, V., Rao, S. & Garg, A. Prolonged thiazolidinedione therapy does not reverse fat loss in patients with familial partial lipodystrophy, Dunnigan variety. *Diabetes Obes. Metab.* **10**, 1275–1276 (2008).
30. Luedtke, A. et al. Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: a case series. *Horm. Metab. Res.* **44**, 306–311 (2012).
31. Agostini, M. et al. A pharmacogenetic approach to the treatment of patients with PPARG mutations. *Diabetes* **67**, 1086–1092 (2018).
32. Francis, G. A. et al. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). *BMC Med. Genet.* **7**, 3 (2006).
33. Savage, D. B. et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. *Diabetes* **52**, 910–917 (2003).
34. Lüdtkke, A. et al. Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone. *Diabetes Med.* **22**, 1611–1613 (2005).
35. Hashimoto, N. et al. A case of type A insulin resistance associated with heterozygous Asn462Ser mutation of the insulin receptor gene. *Diabetol. Int.* **3**, 239–243 (2012).
36. Jo, W. et al. Development of endometrial carcinoma in a patient with leprechaunism (Donohue syndrome). *Clin. Pediatr. Endocrinol.: Case Rep. Clin. Invest.: Off. J. Jpn Soc. Pediatr. Endocrinol.* **22**, 33–38 (2013).
37. Perge, K. et al. Intrauterine growth restriction and hypertrophic cardiomyopathy as prenatal ultrasound findings in a case of leprechaunism. *Mol. Syndromol.* **11**, 223–227 (2020).
38. Plamper, M., Gohlke, B., Schreiner, F. & Woelfle, J. Mecermin in insulin receptor-related severe insulin resistance syndromes: case report and review of the literature. *Int. J. Mol. Sci.* **19** <https://doi.org/10.3390/ijms19051268> (2018).
39. Carmody, D., Ladsaria, S. S., Buikema, R. K., Semple, R. K. & Greeley, S. A. Successful rhIGF1 treatment for over 5 years in a patient with severe insulin resistance due to homozygous insulin receptor mutation. *Diabetes Med.* **33**, e8–e12 (2016).
40. de Kerdanet, M. et al. Ten-year improvement of insulin resistance and growth with recombinant human insulin-like growth factor I in a patient with insulin receptor mutations resulting in leprechaunism. *Diabetes Metab.* **41**, 331–337 (2015).
41. Weber, D. R., Stanescu, D. E., Semple, R., Holland, C. & Magge, S. N. Continuous subcutaneous IGF-1 therapy via insulin pump in a patient with Donohue syndrome. *J. Pediatr. Endocrinol. Metab.* **27**, 1237–1241 (2014).
42. Regan, F. M. et al. Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF binding protein-3 complex improves metabolic control in subjects with severe insulin resistance. *J. Clin. Endocrinol. Metab.* **95**, 2113–2122 (2010).
43. Vestergaard, H., Rossen, M., Urhammer, S. A., Müller, J. & Pedersen, O. Short- and long-term metabolic effects of recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus. *Eur. J. Endocrinol.* **136**, 475–482 (1997).
44. Kuzuya, H. et al. Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. *Diabetes* **42**, 696–705 (1993).
45. Takahashi, Y. et al. A homozygous kinase-defective mutation in the insulin receptor gene in a patient with leprechaunism. *Diabetologia* **40**, 412–420 (1997).
46. Nakashima, N., Umeda, F., Yanase, T. & Nawata, H. Insulin resistance associated with substitution of histidine for arginine 252 in the alpha-subunit of the human insulin receptor: trial of insulin-like growth factor I injection therapy to enhance insulin sensitivity. *J. Clin. Endocrinol. Metab.* **80**, 3662–3667 (1995).
47. Metwalley, K. A. & Farghaly, H. S. Berardinelli-Seip syndrome type 1 in an Egyptian child. *Indian J. Hum. Genet.* **20**, 75–78 (2014).
48. Kirel, B. et al. A case of Donohue syndrome “Leprechaunism” with a novel mutation in the insulin receptor gene. *Turk. Pediatr. Ars.* **52**, 226–230 (2017).
49. Saito-Hakoda, A. et al. A follow-up during puberty in a Japanese girl with type A insulin resistance due to a novel mutation in INSR. *Clin. Pediatr. Endocrinol.: Case Rep. Clin. Invest.: Off. J. Jpn Soc. Pediatr. Endocrinol.* **27**, 53–57 (2018).
50. Kawana, Y., Imai, J., Sawada, S., Yamada, T. & Katagiri, H. Sodium-glucose cotransporter 2 inhibitor improves complications of lipodystrophy: a case report. *Ann. Intern. Med.* **166**, 450–451 (2017).
51. Hamaguchi, T. et al. Treatment of a case of severe insulin resistance as a result of a PIK3R1 mutation with a sodium-glucose cotransporter 2 inhibitor. *J. Diabetes Invest.* **9**, 1224–1227 (2018).
52. Ciudin, A. et al. Successful treatment for the Dunnigan-type familial partial lipodystrophy with Roux-en-Y gastric bypass. *Clin. Endocrinol. (Oxf)* **75**, 403–404 (2011).
53. Grundfest-Broniatowski, S., Yan, J., Kroh, M., Kilim, H. & Stephenson, A. Successful treatment of an unusual case of FPLD2: the role of Roux-en-Y gastric bypass-case report and literature review. *J. Gastrointest. Surg.* **21**, 739–743 (2017).
54. Kozusko, K. et al. Clinical and molecular characterization of a novel PLIN1 frameshift mutation identified in patients with familial partial lipodystrophy. *Diabetes* **64**, 299–310 (2015).
55. Kadowaki, T. et al. Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. *Science* **240**, 787–790 (1988).

56. Yoshimasa, Y. et al. Insulin-resistant diabetes due to a point mutation that prevents insulin proreceptor processing. *Science* **240**, 784–787 (1988).
57. Shackleton, S. et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. *Nat. Genet.* **24**, 153–156 (2000).
58. Lightbourne, M. & Brown, R. J. Genetics of Lipodystrophy. *Endocrinol. Metab. Clin. North Am.* **46**, 539–554 (2017).
59. Barroso, I. et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. *Nature* **402**, 880–883 (1999).
60. Hegele, R. A., Cao, H., Frankowski, C., Mathews, S. T. & Leff, T. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. *Diabetes* **51**, 3586–3590 (2002).
61. Majithia, A. R. et al. Prospective functional classification of all possible missense variants in PPARG. *Nat. Genet.* **48**, 1570–1575 (2016).
62. Mikita, J. S. et al. Determining the suitability of registries for embedding clinical trials in the united states: a project of the clinical trials transformation initiative. *Ther. Innov. Regul. Sci.* **55**, 6–18 (2021).
63. Kidwell, K. M. et al. Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles. *Orphanet J. Rare Dis.* **17**, 186 (2022).
64. Partington, G., Cro, S., Mason, A., Phillips, R. & Cornelius, V. Design and analysis features used in small population and rare disease trials: a targeted review. *J. Clin. Epidemiol.* **144**, 93–101 (2022).
65. Adams, H. R. et al. A novel, hybrid, single- and multi-site clinical trial design for CLN3 disease, an ultra-rare lysosomal storage disorder. *Clin. Trials* **16**, 555–560 (2019).
66. von Schnurbein, J. et al. European lipodystrophy registry: background and structure. *Orphanet J. Rare Dis.* **15**, 17 (2020).
67. Doherty, D. A. et al. Registry randomised trials: a methodological perspective. *BMJ open* **13**, e068057 (2023).
68. James, S., Rao, S. V. & Granger, C. B. Registry-based randomized clinical trials—a new clinical trial paradigm. *Nat. Rev. Cardiol.* **12**, 312–316 (2015).

Acknowledgements

This research was funded in part, by the Wellcome Trust [Grant WT 210752 to RKS and WT 219606 to KAP]. For the purpose of open access, the author has applied a CC0 Public Domain Dedication to any Author Accepted Manuscript version arising from this submission. RJB and SA are supported by the intramural research program of the National Institute of Diabetes and Digestive and Kidney Diseases. The ADA/EASD Precision Diabetes Medicine Initiative, within which this work was conducted, has received the following support: The Covidence license was funded by Lund University (Sweden) for which technical support was provided by Maria Björklund and Krister Aronsson (Faculty of Medicine Library, Lund University, Sweden). Administrative support was provided by Lund University (Malmö, Sweden), University of Chicago (IL, USA), and the American Diabetes Association (Washington D.C., USA). The Novo Nordisk Foundation (Hellerup, Denmark) provided grant support for in-person writing group meetings (PI: L. Phillipson, University of Chicago, IL).

Author contributions

R.K.S., R.J.B. and K.A.P. researched data, wrote the manuscript, and reviewed and approved the final manuscript. S.A. conducted statistical analyses and reviewed and approved the final manuscript. Members of the ADA/EASD PMDI Consortium provided feedback on methodology and reporting guidelines.

Competing interests

The authors declare the following competing interests: R.K.S. has received speaker fees from Eli Lilly, Novo Nordisk, and Amryt. R. J. B. has received research support from Amryt, Third Rock Ventures, Ionis, and Regeneron. K.A.P. and S.A. report no conflicts of interest.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s43856-023-00368-9>.

Correspondence and requests for materials should be addressed to Rebecca J. Brown.

Peer review information *Communications Medicine* thanks Fabrizio Barbetti and Antonio Atalaia for their contribution to the peer review of this work. A peer review file is available.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023

ADA/EASD PMDI

Deirdre K. Tobias^{6,7}, Jordi Merino^{8,9,10}, Abrar Ahmad¹¹, Catherine Aiken^{12,13}, Jamie L. Benham¹⁴, Dhanasekaran Bodhini¹⁵, Amy L. Clark¹⁶, Kevin Colclough³, Rosa Corcoy^{17,18,19}, Sara J. Cromer^{9,20,21}, Daisy Duan²², Jamie L. Felton^{23,24,25}, Ellen C. Francis²⁶, Pieter Gillard²⁷, Véronique Gingras^{28,29}, Romy Gaillard³⁰, Eram Haider³¹, Alice Hughes³, Jennifer M. Ikle^{32,33}, Laura M. Jacobsen³⁴, Anna R. Kahkoska³⁵, Jarno L. T. Kettunen^{36,37,38}, Raymond J. Kreienkamp^{9,10,20,39}, Lee-Ling Lim^{40,41,42}, Jonna M. E. Männistö^{43,44}, Robert Massey³¹, Niamh-Maire McLennan¹, Rachel G. Miller⁴⁵, Mario Luca Morieri^{46,47}, Jasper Most⁴⁸, Rochelle N. Naylor⁴⁹, Bige Ozkan^{50,51}, Kashyap Amratlal Patel³, Scott J. Pilla^{52,53}, Katsiaryna Prystupa^{54,55}, Sridaran Raghaven^{56,57}, Mary R. Rooney^{50,58}, Martin Schön^{54,55,59}, Zhila Semnani-Azad⁷, Magdalena Sevilla-Gonzalez^{20,21,60}, Pernille Svalastoga^{61,62}, Wubet Worku Takele⁶³, Claudia Ha-ting Tam^{42,64,65}, Anne Cathrine B. Thuesen⁸, Mustafa Tosur^{66,67,68}, Amelia S. Wallace^{50,58}, Caroline C. Wang⁵⁸, Jessie J. Wong⁶⁹, Jennifer M. Yamamoto⁷⁰, Katherine Young³, Chloé Amouyal^{71,72}, Mette K. Andersen⁸, Maxine P. Bonham⁷³, Mingling Chen⁷⁴, Feifei Cheng⁷⁵, Tinashe Chikowore^{21,76,77,78}, Sian C. Chivers⁷⁹, Christoffer Clemmensen⁸, Dana Dabelea⁸⁰, Adem Y. Dawed³¹, Aaron J. Deutsch^{10,20,21}, Laura T. Dickens⁸¹, Linda A. DiMeglio^{23,24,25,82}, Monika Dudenhöffer-Pfeifer¹¹, Carmella Evans-Molina^{23,24,25,83},

María Mercè Fernández-Balsells^{84,85}, Hugo Fitipaldi¹¹, Stephanie L. Fitzpatrick⁸⁶, Stephen E. Gitelman⁸⁷, Mark O. Goodarzi^{88,89}, Jessica A. Grieger^{90,91}, Marta Guasch-Ferré^{7,92}, Nahal Habibi^{90,91}, Torben Hansen⁸, Chuiguo Huang^{42,64}, Arianna Harris-Kawano^{23,24,25}, Heba M. Ismail^{23,24,25}, Benjamin Hoag^{93,94}, Randi K. Johnson^{95,96}, Angus G. Jones^{3,97}, Robert W. Koivula⁹⁸, Aaron Leong^{9,21,99}, Gloria K. W. Leung⁷³, Ingrid M. Libman¹⁰⁰, Kai Liu⁹⁰, S. Alice Long¹⁰¹, William L. Lowe Jr.¹⁰², Robert W. Morton^{103,104,105}, Ayesha A. Motala¹⁰⁶, Suna Onengut-Gumuscu¹⁰⁷, James S. Pankow¹⁰⁸, Maleesa Pathirana^{90,91}, Sofia Pazmino¹⁰⁹, Dianna Perez^{23,24,25}, John R. Petrie¹¹⁰, Camille E. Powe^{9,20,21,111}, Alejandra Quinteros⁹⁰, Rashmi Jain^{112,113}, Debashree Ray^{58,114}, Mathias Ried-Larsen^{115,116}, Zeb Saeed¹¹⁷, Vanessa Santhakumar⁶, Sarah Kanbour^{52,118}, Sudipa Sarkar⁵², Gabriela S. F. Monaco^{23,24,25}, Denise M. Scholtens¹¹⁹, Elizabeth Selvin^{50,58}, Wayne Huey-Herng Sheu^{120,121,122}, Cate Speake¹²³, Maggie A. Stanislawski⁹⁵, Nele Steenackers¹⁰⁹, Andrea K. Steck¹²⁴, Norbert Stefan^{55,125,126}, Julie Støy¹²⁷, Rachael Taylor¹²⁸, Sok Cin Tye^{129,130}, Gebresilasea Gendisha Ukke⁶³, Marzhan Urazbayeva^{67,131}, Bart Van der Schueren^{109,132}, Camille Vazier^{133,134}, John M. Wentworth^{135,136,137}, Wesley Hannah^{138,139}, Sara L. White^{79,140}, Gechang Yu^{42,64}, Yingchai Zhang^{42,64}, Shao J. Zhou^{91,141}, Jacques Beltrand^{142,143}, Michel Polak^{142,143}, Ingvild Aukrust^{61,144}, Elisa de Franco³, Sarah E. Flanagan³, Kristin A. Maloney¹⁴⁵, Andrew McGovern³, Janne Molnes^{61,144}, Mariam Nakabuye⁸, Pål Rasmus Njølstad^{61,62}, Hugo Pomares-Millan^{11,146}, Michele Provenzano¹⁴⁷, Cécile Saint-Martin¹⁴⁸, Culin Zhang^{149,150}, Yeyi Zhu^{151,152}, Sungyoung Auh¹⁵³, Russell de Souza^{104,154}, Andrea J. Fawcett^{155,156}, Chandra Gruber¹⁵⁷, Eskedar Getie Mekonnen^{158,159}, Emily Mixter¹⁶⁰, Diana Sherifali^{104,161}, Robert H. Eckel¹⁶², John J. Nolan^{163,164}, Louis H. Philipson¹⁶⁰, Rebecca J. Brown¹⁵³, Liana K. Billings^{165,166}, Kristen Boyle⁸⁰, Tina Costacou⁴⁵, John M. Dennis³, Jose C. Florez^{9,10,20,21}, Anna L. Gloyn^{32,33,167}, Maria F. Gomez^{11,168}, Peter A. Gottlieb¹²⁴, Siri Atma W. Greeley¹⁶⁹, Kurt Griffin^{113,170}, Andrew T. Hattersley^{3,97}, Irl B. Hirsch¹⁷¹, Marie-France Hivert^{9,172,173}, Korey K. Hood⁶⁹, Jami L. Josefson¹⁵⁵, Soo Heon Kwak¹⁷⁴, Lori M. Laffel¹⁷⁵, Siew S. Lim⁶³, Ruth J. F. Loos^{8,176}, Ronald C. W. Ma^{42,64,65}, Chantal Mathieu²⁷, Nestoras Mathioudakis⁵², James B. Meigs^{21,99,177}, Shivani Misra^{178,179}, Viswanathan Mohan¹⁸⁰, Rinki Murphy^{181,182,183}, Richard Oram^{3,97}, Katharine R. Owen^{98,184}, Susan E. Ozanne¹⁸⁵, Ewan R. Pearson³¹, Wei Perng⁸⁰, Toni I. Pollin^{145,186}, Rodica Pop-Busui¹⁸⁷, Richard E. Pratley¹⁸⁸, Leanne M. Redman¹⁸⁹, Maria J. Redondo^{66,67}, Rebecca M. Reynolds¹, Robert K. Semple^{1,2}, Jennifer L. Sherr¹⁹⁰, Emily K. Sims^{23,24,25}, Arianne Sweeting^{191,192}, Tiinamaija Tuomi^{36,136,38}, Miriam S. Udler^{9,10,20,21}, Kimberly K. Vesco¹⁹³, Tina Vilsbøll^{194,195}, Robert Wagner^{54,55,196}, Stephen S. Rich¹⁰⁷ & Paul W. Franks^{7,11,98,105}

⁶Division of Preventative Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

⁷Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA. ⁸Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ⁹Diabetes Unit, Endocrine Division, Massachusetts General Hospital, Boston, MA, USA. ¹⁰Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.

¹¹Department of Clinical Sciences, Lund University Diabetes Centre, Lund University Malmö, Sweden. ¹²Department of Obstetrics and Gynaecology, the Rosie Hospital, Cambridge, UK. ¹³NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK. ¹⁴Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. ¹⁵Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, India. ¹⁶Division of Pediatric Endocrinology, Department of Pediatrics, Saint Louis University School of Medicine, SSM Health Cardinal Glennon Children's Hospital, St. Louis, MO, USA. ¹⁷CIBER-BBN, ISCIII, Madrid, Spain. ¹⁸Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Barcelona, Spain. ¹⁹Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. ²⁰Programs in Metabolism and Medical & Population Genetics, Broad Institute, Cambridge, MA, USA. ²¹Department of Medicine, Harvard Medical School, Boston, MA, USA. ²²Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ²³Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA. ²⁴Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA. ²⁵Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN, USA. ²⁶Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA. ²⁷University Hospital Leuven, Leuven, Belgium. ²⁸Department of Nutrition, Université de Montréal, Montreal, QC, Canada. ²⁹Research Center, Sainte-Justine University Hospital Center, Montreal, QC, Canada. ³⁰Department of Pediatrics, Erasmus Medical Center, Rotterdam, The Netherlands. ³¹Division of Population Health & Genomics, School of Medicine, University of Dundee, Dundee, UK. ³²Department of Pediatrics, Stanford School of Medicine, Stanford University, Stanford, CA, USA. ³³Stanford Diabetes Research Center, Stanford School of Medicine, Stanford University, Stanford, CA, USA. ³⁴University of Florida, Gainesville, FL, USA. ³⁵Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ³⁶Helsinki University Hospital, Abdominal Centre/Endocrinology, Helsinki, Finland. ³⁷Folkhalsan Research Center,

Helsinki, Finland. ³⁸Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland. ³⁹Department of Pediatrics, Division of Endocrinology, Boston Children's Hospital, Boston, MA, USA. ⁴⁰Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. ⁴¹Asia Diabetes Foundation, Hong Kong SAR, China. ⁴²Department of Medicine & Therapeutics, Chinese University of Hong Kong, Hong Kong SAR, China. ⁴³Departments of Pediatrics and Clinical Genetics, Kuopio University Hospital, Kuopio, Finland. ⁴⁴Department of Medicine, University of Eastern Finland, Kuopio, Finland. ⁴⁵Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA. ⁴⁶Metabolic Disease Unit, University Hospital of Padova, Padova, Italy. ⁴⁷Department of Medicine, University of Padova, Padova, Italy. ⁴⁸Department of Orthopedics, Zuyderland Medical Center, Sittard-Geleen, The Netherlands. ⁴⁹Departments of Pediatrics and Medicine, University of Chicago, Chicago, IL, USA. ⁵⁰Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. ⁵¹Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins School of Medicine, Baltimore, MD, USA. ⁵²Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. ⁵³Department of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. ⁵⁴Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Auf'm Hennekamp 65, 40225 Düsseldorf, Germany. ⁵⁵German Center for Diabetes Research (DZD), Ingolstädter Landstraße 1, 85764 Neuherberg, Germany. ⁵⁶Section of Academic Primary Care, US Department of Veterans Affairs Eastern Colorado Health Care System, Aurora, CO, USA. ⁵⁷Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA. ⁵⁸Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. ⁵⁹Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia. ⁶⁰Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA. ⁶¹Mohn Center for Diabetes Precision Medicine, Department of Clinical Science, University of Bergen, Bergen, Norway. ⁶²Children and Youth Clinic, Haukeland University Hospital, Bergen, Norway. ⁶³Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia. ⁶⁴Laboratory for Molecular Epidemiology in Diabetes, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China. ⁶⁵Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong, China. ⁶⁶Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. ⁶⁷Division of Pediatric Diabetes and Endocrinology, Texas Children's Hospital, Houston, TX, USA. ⁶⁸Children's Nutrition Research Center, USDA/ARS, Houston, TX, USA. ⁶⁹Stanford University School of Medicine, Stanford, CA, USA. ⁷⁰Internal Medicine, University of Manitoba, Winnipeg, MB, Canada. ⁷¹Department of Diabetology, APHP, Paris, France. ⁷²Sorbonne Université, INSERM, NutriOmic team, Paris, France. ⁷³Department of Nutrition, Dietetics and Food, Monash University, Melbourne, VIC, Australia. ⁷⁴Monash Centre for Health Research and Implementation, Monash University, Clayton, VIC, Australia. ⁷⁵Health Management Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China. ⁷⁶MRC/Wits Developmental Pathways for Health Research Unit, Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. ⁷⁷Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA. ⁷⁸Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. ⁷⁹Department of Women and Children's health, King's College London, London, UK. ⁸⁰Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ⁸¹Section of Adult and Pediatric Endocrinology, Diabetes and Metabolism, Kovler Diabetes Center, University of Chicago, Chicago, USA. ⁸²Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA. ⁸³Richard L. Roudebush VAMC, Indianapolis, IN, USA. ⁸⁴Biomedical Research Institute Girona, IDIBGI, Girona, Spain. ⁸⁵Diabetes, Endocrinology and Nutrition Unit Girona, University Hospital Dr Josep Trueta, Girona, Spain. ⁸⁶Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA. ⁸⁷University of California at San Francisco, Department of Pediatrics, Diabetes Center, San Francisco, CA, USA. ⁸⁸Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, CA, USA. ⁸⁹Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. ⁹⁰Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia. ⁹¹Robinson Research Institute, The University of Adelaide, Adelaide, Australia. ⁹²Department of Public Health and Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, 1014 Copenhagen, Denmark. ⁹³Division of Endocrinology and Diabetes, Department of Pediatrics, Sanford Children's Hospital, Sioux Falls, SD, USA. ⁹⁴University of South Dakota School of Medicine, E Clark St, Vermillion, SD, USA. ⁹⁵Department of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ⁹⁶Department of Epidemiology, Colorado School of Public Health, Aurora, CO, USA. ⁹⁷Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK. ⁹⁸Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK. ⁹⁹Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA. ¹⁰⁰UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA. ¹⁰¹Center for Translational Immunology, Benaroya Research Institute, Seattle, WA, USA. ¹⁰²Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ¹⁰³Department of Pathology & Molecular Medicine, McMaster University, Hamilton, Canada. ¹⁰⁴Population Health Research Institute, Hamilton, Canada. ¹⁰⁵Department of Translational Medicine, Medical Science, Novo Nordisk Foundation, Tuborg Havnevej 19, 2900 Hellerup, Denmark. ¹⁰⁶Department of Diabetes and Endocrinology, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. ¹⁰⁷Center for Public Health Genomics, Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA. ¹⁰⁸Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA. ¹⁰⁹Department of Chronic Diseases and Metabolism, Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium. ¹¹⁰School of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. ¹¹¹Department of Obstetrics, Gynecology, and Reproductive Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. ¹¹²Sanford Children's Specialty Clinic, Sioux Falls, SD, USA. ¹¹³Department of Pediatrics, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, USA. ¹¹⁴Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. ¹¹⁵Centre for Physical Activity Research, Rigshospitalet, Copenhagen, Denmark. ¹¹⁶Institute for Sports and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark. ¹¹⁷Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Indiana University School of Medicine, Indianapolis, IN, USA. ¹¹⁸AMAN Hospital, Doha, Qatar. ¹¹⁹Department of Preventive Medicine, Division of Biostatistics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ¹²⁰Institute of Molecular and Genomic Medicine, National Health Research Institutes, Taipei City, Taiwan. ¹²¹Division of Endocrinology and Metabolism, Taichung Veterans General Hospital, Taichung, Taiwan. ¹²²Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan. ¹²³Center for Interventional Immunology, Benaroya Research Institute, Seattle, WA, USA. ¹²⁴Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ¹²⁵University Hospital of Tübingen, Tübingen, Germany. ¹²⁶Institute of Diabetes Research and Metabolic Diseases (IDM), Helmholtz Center Munich, Neuherberg, Germany. ¹²⁷Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark. ¹²⁸University of Newcastle, Newcastle upon Tyne, UK. ¹²⁹Sections on Genetics and Epidemiology, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA. ¹³⁰Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands. ¹³¹Gastroenterology, Baylor College of Medicine, Houston, TX, USA. ¹³²Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium. ¹³³Sorbonne University, Inserm U938, Saint-Antoine Research Centre, Institute of Cardiometabolism and Nutrition, Paris 75012, France. ¹³⁴Department of Endocrinology, Diabetology and Reproductive Endocrinology, Assistance Publique-Hôpitaux de Paris, Saint-Antoine University Hospital, National

Reference Center for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris, France. ¹³⁵Royal Melbourne Hospital Department of Diabetes and Endocrinology, Parkville, Vic, Australia. ¹³⁶Walter and Eliza Hall Institute, Parkville, VIC, Australia. ¹³⁷University of Melbourne Department of Medicine, Parkville, VIC, Australia. ¹³⁸Deakin University, Melbourne, Australia. ¹³⁹Department of Epidemiology, Madras Diabetes Research Foundation, Chennai, India. ¹⁴⁰Department of Diabetes and Endocrinology, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, UK. ¹⁴¹School of Agriculture, Food and Wine, University of Adelaide, Adelaide, Australia. ¹⁴²Institut Cochin, Inserm U 10116 Paris, France. ¹⁴³Pediatric endocrinology and diabetes, Hopital Necker Enfants Malades, APHP Centre, université de Paris, Paris, France. ¹⁴⁴Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway. ¹⁴⁵Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. ¹⁴⁶Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA. ¹⁴⁷Nephrology, Dialysis and Renal Transplant Unit, IRCCS—Azienda Ospedaliero-Universitaria di Bologna, Alma Mater Studiorum University of Bologna, Bologna, Italy. ¹⁴⁸Department of Medical Genetics, AP-HP Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France. ¹⁴⁹Global Center for Asian Women's Health, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. ¹⁵⁰Department of Obstetrics and Gynecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. ¹⁵¹Kaiser Permanente Northern California Division of Research, Oakland, CA, USA. ¹⁵²Department of Epidemiology and Biostatistics, University of California San Francisco, California, CA, USA. ¹⁵³National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. ¹⁵⁴Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada. ¹⁵⁵Ann & Robert H. Lurie Children's Hospital of Chicago, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ¹⁵⁶Department of Clinical and Organizational Development, Chicago, IL, USA. ¹⁵⁷American Diabetes Association, Arlington, VA, USA. ¹⁵⁸College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. ¹⁵⁹Global Health Institute, Faculty of Medicine and Health Sciences, University of Antwerp, 2160 Antwerp, Belgium. ¹⁶⁰Department of Medicine and Kovler Diabetes Center, University of Chicago, Chicago, IL, USA. ¹⁶¹School of Nursing, Faculty of Health Sciences, McMaster University, Hamilton, Canada. ¹⁶²Division of Endocrinology, Metabolism, Diabetes, University of Colorado, Boulder, CO, USA. ¹⁶³Department of Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland. ¹⁶⁴Department of Endocrinology, Wexford General Hospital, Wexford, Ireland. ¹⁶⁵Division of Endocrinology, NorthShore University HealthSystem, Skokie, IL, USA. ¹⁶⁶Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, IL, USA. ¹⁶⁷Department of Genetics, Stanford School of Medicine, Stanford University, Stanford, CA, USA. ¹⁶⁸Faculty of Health, Aarhus University, Aarhus, Denmark. ¹⁶⁹Departments of Pediatrics and Medicine and Kovler Diabetes Center, University of Chicago, Chicago, USA. ¹⁷⁰Sanford Research, Sioux Falls, SD, USA. ¹⁷¹University of Washington School of Medicine, Seattle, WA, USA. ¹⁷²Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care Institute, Boston, MA, USA. ¹⁷³Department of Medicine, Université de Sherbrooke, Sherbrooke, QC, Canada. ¹⁷⁴Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea. ¹⁷⁵Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA. ¹⁷⁶Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹⁷⁷Broad Institute, Cambridge, MA, USA. ¹⁷⁸Division of Metabolism, Digestion and Reproduction, Imperial College London, London, UK. ¹⁷⁹Department of Diabetes & Endocrinology, Imperial College Healthcare NHS Trust, London, UK. ¹⁸⁰Department of Diabetology, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, Chennai, India. ¹⁸¹Department of Medicine, Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand. ¹⁸²Auckland Diabetes Centre, Te Whatu Ora Health New Zealand, Auckland, New Zealand. ¹⁸³Medical Bariatric Service, Te Whatu Ora Counties, Health New Zealand, Auckland, New Zealand. ¹⁸⁴Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK. ¹⁸⁵University of Cambridge, Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science, Cambridge, UK. ¹⁸⁶Department of Epidemiology & Public Health, University of Maryland School of Medicine, Baltimore, MD, USA. ¹⁸⁷Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA. ¹⁸⁸AdventHealth Translational Research Institute, Orlando, FL, USA. ¹⁸⁹Pennington Biomedical Research Center, Baton Rouge, LA, USA. ¹⁹⁰Yale School of Medicine, New Haven, CT, USA. ¹⁹¹Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. ¹⁹²Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, NSW, Australia. ¹⁹³Kaiser Permanente Northwest, Kaiser Permanente Center for Health Research, Portland, OR, USA. ¹⁹⁴Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark. ¹⁹⁵Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ¹⁹⁶Department of Endocrinology and Diabetology, University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany.